Intervention of natural products targeting novel mechanisms after myocardial infarction.
10.1016/S1875-5364(25)60816-8
- Author:
Guangjie TAI
1
;
Renhua LIU
1
;
Tian LIN
1
;
Jiancheng YANG
2
;
Xiaoxue LI
3
;
Ming XU
4
Author Information
1. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
2. Department of Biomedical Engineering, The University of Texas at Austin, Austin 78712, USA.
3. Department of Cardiology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, China.
4. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: mingxu@cpu.edu.cn.
- Publication Type:Review
- Keywords:
Myocardial infarction;
Natural products;
Novel mechanisms
- MeSH:
Humans;
Myocardial Infarction/genetics*;
Biological Products/therapeutic use*;
Animals;
Oxidative Stress/drug effects*;
Signal Transduction/drug effects*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2025;23(6):658-672
- CountryChina
- Language:English
-
Abstract:
Myocardial infarction is a cardiovascular disease (CVD) with high morbidity and mortality, which can trigger a cascade of cardiac pathophysiological changes, including fibrosis, inflammation, ischemia-reperfusion injury (IRI), and ventricular remodeling, ultimately leading to heart failure (HF). While conventional pharmacological treatments and clinical reperfusion therapy may enhance short-term prognoses and emergency survival rates, both approaches have limitations and adverse effects. Natural products (NPs) are extensively utilized as therapeutics globally, with some demonstrating potentially favorable therapeutic effects in preclinical and clinical pharmacological studies, positioning them as potential alternatives to modern drugs. This review comprehensively elucidates the pathophysiological mechanisms during myocardial infarction and summarizes the mechanisms by which NPs exert cardiac beneficial effects. These include classical mechanisms such as inhibition of inflammation and oxidative stress, alleviation of cardiomyocyte death, attenuation of cardiac fibrosis, improvement of angiogenesis, and emerging mechanisms such as cardiac metabolic regulation and histone modification. Furthermore, the review emphasizes the modulation by NPs of novel targets or signaling pathways in classical mechanisms, including other forms of regulated cell death (RCD), endothelial-mesenchymal transition, non-coding ribonucleic acids (ncRNAs) cascade, and endothelial progenitor cell (EPC) function. Additionally, NPs influencing a particular mechanism are categorized based on their chemical structure, and their relevance is discussed. Finally, the current limitations and prospects of NPs therapy are considered, highlighting their potential for use in myocardial infarction management and identifying issues that require urgent attention.
